We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Nonhospitalized patients with COVID-19 who received the ...

U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) filing to study the use of Alvesco in COVID-19 Study will evaluate the Safety and Efficacy of Alvesco ...

COVID-19 outpatients treated with the inhaled corticosteroid ciclesonide (Alvesco) obtained no symptom relief beyond that seen in a placebo group, a large randomized trial showed. Odds of needing ...

Active ingredient: Ciclesonide 80 µg/inhalation, 160 µg/inhalation; metered-dose inhaler. Indication: Maintenance treatment of asthma as prophylactic therapy in patients >12 years of age. Pharmacology ...

September 18, 2006 — Health Canada has approved inhaled ciclesonide for the prophylaxis of steroid-responsive bronchial asthma in patients aged 18 years or older; the European Commission has approved ...